Who are Rosiglitazone (BRL49653C)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pioglitazone and Glimepiride, Metformin, Pioglitazone, aleglitazar+metformin, Rosiglitazone XR, rosiglitazone maleate/metformin hydrochloride, rosiglitazone-metformin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rosiglitazone-brl49653c.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rosiglitazone (BRL49653C) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rosiglitazone (BRL49653C) (Rosiglitazone (BRL49653C)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinedione. Area: Diabetes.

phase 3 Thiazolidinedione PPARγ Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Rosiglitazone (BRL49653C) (Rosiglitazone (BRL49653C)) — GlaxoSmithKline. Rosiglitazone activates PPARγ, a nuclear receptor that regulates glucose and lipid metabolism.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Rosiglitazone (BRL49653C) TARGET	Rosiglitazone (BRL49653C)	GlaxoSmithKline	phase 3	Thiazolidinedione	PPARγ
Pioglitazone and Glimepiride	Pioglitazone and Glimepiride	Takeda	marketed	Sulfonylurea [EPC]	PPARγ, ATP-sensitive potassium channel
Metformin, Pioglitazone	Metformin, Pioglitazone	Khyber Medical University Peshawar	marketed	Antidiabetic combination (biguanide + thiazolidinedione)	AMPK (metformin); PPARγ (pioglitazone)
aleglitazar+metformin	aleglitazar+metformin	Hoffmann-La Roche	phase 3	PPARα/γ agonist and biguanide	PPARα, PPARγ
Rosiglitazone XR	Rosiglitazone XR	GlaxoSmithKline	marketed	Thiazolidinedione (PPAR-γ agonist)	PPAR-γ (Peroxisome proliferator-activated receptor gamma)
rosiglitazone maleate/metformin hydrochloride	rosiglitazone maleate/metformin hydrochloride	GlaxoSmithKline	marketed	Thiazolidinedione/Biguanide combination	PPAR-γ (rosiglitazone); Complex I of mitochondrial respiratory chain (metformin)
rosiglitazone-metformin	rosiglitazone-metformin	GlaxoSmithKline	marketed	Thiazolidinedione + Biguanide combination	PPAR-γ (rosiglitazone component); Complex mitochondrial mechanism (metformin component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinedione class)

Merck Sharp & Dohme LLC · 3 drugs in this class
GlaxoSmithKline · 1 drug in this class
Medical University of South Carolina · 1 drug in this class
National Cheng-Kung University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rosiglitazone (BRL49653C) — Competitive Intelligence Brief. https://druglandscape.com/ci/rosiglitazone-brl49653c. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab